Eli Lilly and Company (BIT:1LLY)
Italy · Delayed Price · Currency is EUR | Market Cap | 686.92B +2.7% |
| Revenue (ttm) | 55.51B +44.7% |
| Net Income | 17.58B +94.9% |
| EPS | 19.55 +96.0% |
| Shares Out | n/a |
| PE Ratio | 39.08 |
| Forward PE | 26.47 |
| Dividend | 3.91 (0.49%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 432 |
| Average Volume | 305 |
| Open | 771.80 |
| Previous Close | 771.90 |
| Day's Range | 770.00 - 780.40 |
| 52-Week Range | 535.20 - 972.00 |
| Beta | n/a |
| RSI | 38.83 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390 prescriptions for its newly launched obesity pill in the U.S. for the week ended April 10.
Lilly CEO sees weight-loss drugs reaching about half of potential users at peak
Weight-loss drugs may eventually reach only about 50% of the overweight and obese people who could benefit from them due to complexities of healthcare systems and financial constraints, Eli Lilly CEO...
Lilly's new GLP-1 pill is off to a ‘robust' start
Lilly's new GLP-1 pill had 1,390 prescriptions in its first week on the market.
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral vision loss, leading to legal blindness by age 40–45.
Lilly confirms date and conference call for first-quarter 2026 financial results announcement
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that ...
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment
Eli Lilly's late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results.
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events In a pre-planned analysis, the ris...
LLY Stock To $2,000?
Can Eli Lilly (NYSE: LLY) stock surge 2x to $2,000 in the coming years? We believe that this is indeed a genuine possibility.
Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company
ROCKVILLE, Md.--(BUSINESS WIRE)--Linden Lake Labs (“L3”), an early-stage life sciences platform committed to advancing innovative therapies, today announced that its portfolio company, CrossBridge Bio...
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates
HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) today announced a defin...
Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm This trial predominantly enrolled a patient population previously treated with covalent ...
LLY v. NVO: Weighing Who's Winning the GLP-1 Industry
Scott Zari returns to the Watch List and offers the latest updates around the GLP-1 trade and the two companies leading it: Eli Lilly (LLY) and Novo Nordisk (NVO). He sees weight loss drug efficacy be...
Genetic variations linked to weight loss, side effects from GLP-1 drugs
Weight-loss responses to GLP-1 obesity drugs, and risks of side effects, may be linked to genetic variants, according to a study conducted by DNA-testing service 23AndMe.
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%.
Eli Lilly's Weight-Loss Pill Hits the Shelves. It's a Turning Point for the Stock.
The pharmaceutical's Foundayo drug takes on oral Wegovy, the popular treatment from Novo Nordisk.
Amazon to stock Lilly's new weight-loss pill at US kiosks, offer same-day delivery
Amazon.com said on Thursday its pharmacy unit will stock Eli Lilly's new weight-loss pill at kiosks located at some of the company's primary care clinics and offer same-day delivery of the drug.
Eli Lilly Weight-Loss Pill Becomes Available in U.S.
Eli Lilly's Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration's approval earlier this month, the company said.
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.
Foundayo is now available via LillyDirect ® and telehealth providers and is shipping to retail pharmacies nationwide Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day wit...
India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparation
Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India.
A new weight-loss pill is here, and it could reshape the GLP-1 market
A new GLP-1 pill is about to hit the market. On Wednesday, Eli Lilly and Co. announced that its new GLP-1 pill, Foundayo, was approved by the Food and Drug Administration (FDA) for use in adults with ...
MSFT, AVGO, LLY & Other Stock Market Opportunities Amid U.S.-Iran War
There's always opportunity in markets if you know where to look, says Tiffany McGhee. She offers insight into how her firm positions portfolios in times of profound volatility, including now as the U....
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC ...
Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh
Eli Lilly And Company (NYSE: LLY) shares are down approximately 1% Thursday despite FDA approval of its oral weight-loss drug Foundayo on Wednesday, as geopolitical tensions weigh on broader markets.
Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison
Oral Wegovy demonstrated "significantly greater mean weight loss" than Lilly's rival pill Foundayo, which was approved this week, Novo Nordisk said Thursday. Novo's findings evaluated previously publi...
Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
Eli Lilly's newly approved weight-loss pill is expected to generate billions in sales as soon as this year, with analysts betting it will quickly narrow Novo Nordisk's head start in the oral market.